These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21299637)
1. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Muñoz P; Rojas L; Cervera C; Garrido G; Fariñas MC; Valerio M; Giannella M; Bouza E; Clin Transplant; 2012; 26(1):87-96. PubMed ID: 21299637 [TBL] [Abstract][Full Text] [Related]
3. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. Nivoix Y; Launoy A; Lutun P; Moulin JC; Phai Pang KA; Fornecker LM; Wolf M; Levêque D; Letscher-Bru V; Beretz L; Ubeaud-Sequier G; Herbrecht R J Antimicrob Chemother; 2012 Oct; 67(10):2506-13. PubMed ID: 22778159 [TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis against fungal infections in solid organ and hematopoietic stem cells transplantation]. Rabagliati R; Santolaya ME Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S11-8. PubMed ID: 23282550 [TBL] [Abstract][Full Text] [Related]
5. Management of mycoses in surgical patients -- review of the literature. Holzheimer RG; Dralle H Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912 [TBL] [Abstract][Full Text] [Related]
6. Is universal antifungal prophylaxis mandatory in lung transplant patients? Schaenman JM Curr Opin Infect Dis; 2013 Aug; 26(4):317-25. PubMed ID: 23743815 [TBL] [Abstract][Full Text] [Related]
7. A survey of anti-fungal management in lung transplantation. Dummer JS; Lazariashvilli N; Barnes J; Ninan M; Milstone AP J Heart Lung Transplant; 2004 Dec; 23(12):1376-81. PubMed ID: 15607667 [TBL] [Abstract][Full Text] [Related]
8. [Management of aspergillosis in immunocompromised patients. Recommendations of Lille University Hospital--4th version--November 2004]. Alfandari S; Leroy O; de Botton S; Yakoub-Agha I; Durand-Joly I; Leroy-Cotteau A; Beaucaire G; Med Mal Infect; 2005 Mar; 35(3):121-34. PubMed ID: 15911182 [TBL] [Abstract][Full Text] [Related]
9. Antifungal treatment strategies in high risk patients. Rüping MJ; Vehreschild JJ; Cornely OA Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331 [TBL] [Abstract][Full Text] [Related]
12. Changing strategies for the management of invasive fungal infections. Rapp RP Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487 [TBL] [Abstract][Full Text] [Related]
13. A new era of antifungal therapy. Wingard JR; Leather H Biol Blood Marrow Transplant; 2004 Feb; 10(2):73-90. PubMed ID: 14750074 [TBL] [Abstract][Full Text] [Related]
14. Antifungal prophylaxis for invasive mycoses in high risk patients. Ullmann AJ; Cornely OA Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333 [TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369 [TBL] [Abstract][Full Text] [Related]